BI32 A case of pembrolizumab-induced psoriasiform rash treated with risankizumab

Vani Agarwal,Georgie Chamberlain,Laksha Bala,Noha El Shimy

DOI: https://doi.org/10.1093/bjd/ljae090.320

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract We present the case of a 77-year-old female patient with a pT3a clear cell renal cell carcinoma who underwent a nephrectomy and adjuvant pembrolizumab therapy. She had a past medical history of hypercholesterolaemia, for which she took atorvastatin. After 11 cycles of pembrolizumab she developed widespread erythematous plaques with overlying scale. The initial clinical diagnosis was a lichenoid drug eruption secondary to immunotherapy. Pembrolizumab was paused for 4 weeks and the rash significantly improved with daily application of 0.1% mometasone ointment. After two further cycles of pembrolizumab, the rash reoccurred with worsening severity. A 4-mm punch biopsy was taken from the right thigh. This showed parakeratotic scales, dense neutrophilic inflammation, hypogranulosis, psoriasiform hyperplasia and a dense dermoepidermal mixed acute and chronic inflammatory infiltrate. This was consistent with a psoriasiform pattern of inflammation. Of note, she did not have a personal or family history of psoriasis. Despite maximum topical therapy and stopping immunotherapy, her Psoriasis Area and Severity Index (PASI) score increased from 10 to 33 over a few weeks. She had a body surface area coverage of 70%. Her Dermatology Life Quality Index (DLQI) score was 24. Owing to the severity of her skin and relative contraindications (history of malignancy) to conventional systemic therapies, the decision was made to commence risankizumab, an interleukin-23 inhibitor. She had an excellent response with an improvement of PASI score to 8.4 and DLQI score to 4, 4 weeks after initial induction. Pembrolizumab is an immune checkpoint inhibitor that inhibits programmed cell death 1. It has been associated with a wide variety of cutaneous adverse events including eczematous, morbilliform and lichenoid dermatoses, as well as vitiligo and pruritus. It has less commonly been associated with psoriasiform dermatoses, bullous disorders and severe cutaneous adverse reactions. In the literature, there have been reported cases of immunotherapy-induced psoriasis that have been successfully treated with apremilast and secukinumab. To our knowledge, this is the second reported such case of successful treatment with risankizumab. As immunotherapy continues to become more widely used for the treatment of malignancies, reporting cases of safe, rapidly responsive and efficacious treatments is of great importance.

dermatology